Patents by Inventor Subhash Khanapure
Subhash Khanapure has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080009498Abstract: The invention provides novel compositions containing at least one phosphodiesterase inhibitor, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3?,5?-monophosphate (cGMP).Type: ApplicationFiled: June 27, 2007Publication date: January 10, 2008Applicant: NitroMed, Inc.Inventors: David Garvey, Inigo de Tejada, Richard Earl, Subhash Khanapure
-
Publication number: 20070238735Abstract: The invention provides novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions and kits comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.Type: ApplicationFiled: May 21, 2007Publication date: October 11, 2007Applicant: NitrodMed, Inc.Inventors: David Garvey, Subhash Khanapure, Ramani Ranatunge, Stewart Richardson, Joseph Schroeder
-
Publication number: 20070037821Abstract: The invention describes novel nitrosated glutamic acid compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated glutamic acid compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated glutamic acid compound, and, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent.Type: ApplicationFiled: September 27, 2004Publication date: February 15, 2007Applicant: NITROMED, INC.Inventors: David Garvey, Richard Earl, Malko Ezawa, Xinqin Fang, Ricky Gaston, Subhash Khanapure, Chia-En Lin, Ramani Ranatunga, Cheri Stevenson, Shiow-Jyi Wey
-
Publication number: 20060194861Abstract: The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated.Type: ApplicationFiled: May 5, 2006Publication date: August 31, 2006Applicant: NitroMed, Inc.Inventors: Ipul Bandarage, Richard Earl, Maiko Ezawa, Xinqin Fang, David Garvey, Subhash Khanapure, Ramani Ranatunge, Stewart Richardson, Joseph Schroeder, Cheri Stevenson, Shiow-Jyi Wey
-
Publication number: 20060189603Abstract: The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia.Type: ApplicationFiled: February 24, 2006Publication date: August 24, 2006Applicant: NitroMed, Inc.Inventors: David Garvey, L. Letts, Richard Earl, Maiko Ezawa, Xinqin Fang, Ricky Gaston, Subhash Khanapure, Chia-En Lin, Ramani Ranatunge, Cheri Stevenson, Shiow-Jyi Wey
-
Publication number: 20050222243Abstract: The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.Type: ApplicationFiled: May 23, 2005Publication date: October 6, 2005Applicant: NitroMed, Inc.Inventors: Richard Earl, Maiko Ezawa, Xinqin Fang, David Garvey, Ricky Gaston, Subhash Khanapure, L. Gordon Letts, Chia-En Lin, Ramani Ranatunga, Stewart Richardson, Joseph Schroeder, Cheri Stevenson, Shiow-Jyi Wey
-
Publication number: 20050187222Abstract: The present invention describes novel nitrosated and/or nitrosylated ?-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated ?-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one ?-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents.Type: ApplicationFiled: April 20, 2005Publication date: August 25, 2005Applicant: NitroMed, Inc.Inventors: David Garvey, Inigo De Tejada, Ricky Gaston, Subhash Khanapure, Tatiana Shelekhin, Tiansheng Wang
-
Publication number: 20050059655Abstract: The invention describes novel nitrosated and/or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent.Type: ApplicationFiled: August 20, 2004Publication date: March 17, 2005Applicant: NitroMed, Inc.Inventors: David Garvey, L. Letts, Manuel Worcel, Richard Earl, Maiko Ezawa, Xinqin Fang, Subhash Khanapure, Chia-En Lin, Ramani Ranatunga, Cheri Stevenson
-
Publication number: 20050059665Abstract: The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal anti-inflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H2 antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pyType: ApplicationFiled: October 21, 2004Publication date: March 17, 2005Applicant: NitroMed, Inc.Inventors: Subhash Khanapure, David Garvey, Richard Earl, Maiko Ezawa, Xinqin Fang, Ricky Gaston